PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15
Media Pack
News

Current Edition

Issue 8, Volume 3

Upcoming Events

Lab Innovations 23.09.25
PEGS Europe – 24.07.2025
BIO-Europe 2025 – 10.07.2025
Cell 2025 – 30.05.2025
Cell Leaders Awards – 30.05.2025

Advertisement

Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
Light Cast – 17.07.2025
news

Biopharma Takes on Deadly Brain Cancer After Decades of Failure

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics and others are targeting the often-fatal...
2 December 2024 news biopharma | biopharmaceutical
Continue Reading →
news

Adcendo Raises $135m for Cancer ADCs, and Other Financings

Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an oversubscribed second round that raised $13...
2 December 2024 news Adcendo | Antibody
Continue Reading →
news

FDA Oncology Advisory Committee to Weigh Exelixis’ Cabometyx in Neuroendocrine Tumours

The advisory committee will meet to discuss Cabometyx's phase 3 CABINET study in March 2025. Before Exelexis’ Cabometyx can pass muster with the FDA in its hopefu...
2 December 2024 news biopharma | cancer
Continue Reading →
news

Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024

Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the Europea...
23 September 2024 news oncology | Pfizer
Continue Reading →
Volume 5 Issue 3

ADCs – From Lab to Clinical Development

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer...
12 October 2022 Volume 5 Issue 3 agents | Antibody
Continue Reading →
news

GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion in a bet that an experimental drug the small biotech developed is on the cusp of becoming a val...
14 April 2022 news cancer | Drug
Continue Reading →
news

Gilead’s Kite bets on early-stage biotech to advance allogeneic cell therapies

The deal with Appia is yet another step in Gilead’s efforts to become an oncology powerhouse — a strategy the company has made clear through numerous acquisitions and...
13 August 2021 news allogeneic cell therapies | Biotech
Continue Reading →
news

Philips, SAM open regional oncology centre in Singapore

First phase of Singapore’s Advanced Medicine Imaging Center provides accurate and timely diagnosis of cancer, plus an education center for medical training and scie...
8 June 2018 news centre | oncology
Continue Reading →
news

ASCO18: 3 unanswered questions from oncology’s largest conference

Each year, the ASCO annual meeting serves as a forum for some of the most important clinical studies in oncology, giving physicians important insights into how best...
8 June 2018 news ASCO | conference
Continue Reading →
Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Drug Discovery 2025, ELRIG – 04.07.2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
InsideReg – 29.07.2025
Crown Bioscience 08.09.2025
IBI-white.png

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Facebook Linkedin
Bio Pharmaceutical Media © 2025, All Rights Reserved – Powered by Teksyte